Quantum-Si Incorporated Stock Price, News & Analysis

Quantum-Si (Nasdaq: QSI), The Protein Sequencing Company™, has announced an upcoming Investor & Analyst event scheduled for November 20th, 2024, from 10AM to 12PM EST at the Westin NY Times Square. The event will feature presentations from the company's management team, focusing on their technology roadmap, protein sequencing applications, and expanding commercial opportunities. The event includes a live Q&A session.

While in-person attendance is restricted to invited research analysts and institutional investors, others can participate virtually through the company's investor relations website. The webcast recording will remain accessible for at least 90 days after the event.

Quantum-Si (Nasdaq: QSI) announced its participation in the 2024 American Society of Human Genetics Annual Meeting, where it will present on Next-Generation Protein Sequencing (NGPS) technology. The presentation, titled 'From Prediction to Protein: Validating Transcriptomics Data with Quantum-Si's Next-Generation Protein Sequencing Technology,' will feature Dr. Meredith Carpenter and Dr. Colette Felton from UC Santa Cruz.

The presentation will demonstrate how NGPS technology validates transcriptomics predictions by confirming protein presence, abundance, and modifications. Dr. Felton will discuss using long-read RNA sequencing to detect variants in cancer genes and applying NGPS for protein-level validation. Quantum-Si will be available at booth #465 during ASHG 2024.

Quantum-Si (Nasdaq: QSI) has scheduled its third quarter 2024 financial results announcement for Tuesday, November 12, 2024. The company will host a conference call and webcast at 8:00 AM ET on the same day to discuss the results and provide a business update. Interested parties can access the webcast through the Investors section of Quantum-Si's website or register for a personalized dial-in number. A replay will be available after the event.

Quantum-Si Incorporated (Nasdaq: QSI), The Protein Sequencing Company™, has announced that its Compensation Committee has granted a total of 385,983 restricted stock units (RSUs) to five new employees under the company's 2023 Inducement Equity Incentive Plan. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducements for the new employees joining Quantum-Si.

The RSUs will vest according to the following schedule: 25% on December 20, 2025, with the remaining 75% vesting in 12 equal quarterly installments thereafter. Vesting is subject to the employees' continued employment with Quantum-Si. The RSUs are governed by the terms and conditions of the 2023 Inducement Plan and the respective RSU agreements.

Quantum-Si (Nasdaq: QSI) announced its participation at the Human Proteome Organization (HUPO) World Congress 2024 in Dresden, Germany. The company, known for Next-Generation Protein Sequencing™ (NGPS), will present data from its Platinum® instrument in two poster sessions:

1. Quantum-Si's Next-Generation Protein Sequencer™ for protein detection and peptide characterization from biological samples.

2. Integrated sequencing of single transcript and protein molecules to discern alternatively spliced tropomyosin proteoforms.

Additionally, Quantum-Si will host a breakfast talk on combining NGPS and top-down mass spectrometry for enhanced proteoform analysis. These presentations will showcase Platinum's capabilities in detecting protein variants, post-translational modifications, protein barcoding, and proteoform characterization.

Quantum-Si (Nasdaq: QSI) has announced an upcoming webinar titled 'Integrating Top-Down Mass Spectrometry and Single-Molecule Sequencing for Proteoform Analysis' scheduled for September 30, 2024. The event will feature Dr. Michael Caldwell from Northwestern University's Proteomics Center of Excellence and Dr. Meredith Carpenter from Quantum-Si.

The webinar will explore the integration of top-down mass spectrometry (TD-MS) with Quantum-Si's Platinum® instrument, showcasing how this combination offers unparalleled precision in detecting and characterizing proteins at the single-molecule level. Jeff Hawkins, CEO of Quantum-Si, emphasized the company's commitment to advancing proteomics through innovative technologies.

Dr. Caldwell highlighted the growing need for advanced technologies in proteoform characterization, stating that Quantum-Si's Platinum is a key part of their efforts in proteoform identification and discovery. The webinar aims to demonstrate how Next-Gen Protein Sequencing™ (NGPS) complements traditional approaches and enables novel discoveries in health and disease research.

Quantum-Si (Nasdaq: QSI), The Protein Sequencing Company™, has announced an Investor & Analyst event scheduled for November 20th, 2024 in New York City. The event will take place from 10 AM to 12 PM EST at the Westin NY Times Square.

During the event, Quantum-Si's management team will provide:

• Updates on market opportunities
• Insights into the technology roadmap, including new instrument offerings
• Data on novel uses of the company's detection technology beyond Next-Generation Protein Sequencing™

The event will be live streamed and include a question-and-answer session. Investors can attend in person or virtually by registering through the provided link. The webcast will be archived for at least 30 days on Quantum-Si's Investor Relations website.

Quantum-Si (Nasdaq: QSI) announced that Liberate Bio has integrated the Platinum® Next-Generation Protein Sequencer™ (NGPS) into their platform for developing novel gene therapies. Liberate is using the sequencer's protein barcoding application to screen lipid nanoparticle delivery vehicles in vivo, enhancing the precision, speed, and efficiency of their gene therapy discovery and development efforts.

The Platinum enables advanced insights into the proteome, providing characterization of protein sequence and variation at single-amino acid resolution. Unlike alternative approaches such as mass spectrometry, it does not require expensive equipment or specialized expertise. The integration has already shown transformative potential, allowing Liberate to accelerate discovery and screening efforts with reduced costs and shortened timelines.

Quantum-Si (Nasdaq: QSI), a protein sequencing company, has announced key executive appointments to drive its evolution as a leading proteomic tool provider. Todd Bennett will join as Chief Commercial Officer on September 16, 2024, bringing over 30 years of commercial leadership experience in life science tools and diagnostics. John Vieceli, Ph.D. has been named Chief Product Officer, leveraging his expertise in product development and launch from leading life sciences companies. Lindsay Thompson has been promoted to Chief Human Resources Officer, recognizing her contributions to the company's culture and talent management.

These strategic appointments aim to accelerate the global adoption of Quantum-Si's Platinum® technology and enhance product development and delivery. The company is focusing on integrating all activities from product development to customer delivery under the new Chief Product Officer role. Grace Johnston, Ph.D., has resigned as Chief Commercial Officer and will provide transitional support until September 6, 2024.